Cytocristin Aqueous 1 mg Injection
$0,50
$0,39
Cytocristin Aqueous 1 mg Injection is a vital component in the fight against various forms of cancer, classified under the Vinca alkaloids group of chemotherapy agents. This injectable medication effectively inhibits the proliferation of cancer cells, thereby slowing tumor growth and contributing to the overall treatment strategy for specific malignancies. It is commonly utilized for conditions such as lymphomas and solid tumors, where its mechanism of action disrupts the mitotic process of rapidly dividing cells. While Cytocristin can be a powerful ally in cancer therapy, it is essential to be aware of potential side effects, including nausea, hair loss, and increased risk of infection, necessitating careful monitoring by healthcare professionals. Patients receiving this treatment should inform their doctors of any pre-existing conditions, particularly those related to liver function, as these may affect dosage and efficacy. As with any chemotherapy regimen, discussing the benefits and risks with a medical provider is crucial for optimal patient care. Cytocristin Aqueous 1 mg Injection remains a significant option in oncological treatment, offering hope to those battling cancer through its targeted action against malignant cells.
數量
Active Pharmaceutical Ingredient
Uses
• Cytocristin aqueous 1 mg injection is utilized in the treatment of various types of cancers, including brain tumors. It helps to target and inhibit the growth of cancer cells, providing a therapeutic option for patients with these challenging conditions. By delivering the active ingredient directly into the bloodstream, Cytocristin can effectively reach tumors located in hard-to-access areas. This makes it a valuable choice for oncologists managing brain tumor cases.
• The medicine is also indicated for use in patients diagnosed with cervical cancer. Cytocristin aqueous 1 mg injection works by disrupting the proliferation of cancerous cells, thereby aiding in the management of this specific malignancy. Oncologists often consider this injection as part of a comprehensive treatment plan. Its targeted approach helps improve outcomes for patients undergoing cervical cancer therapy.
• Cytocristin aqueous 1 mg injection is frequently employed in the treatment of colorectal cancer. This medication assists in reducing tumor size and controlling disease progression, which is crucial for patient management. As part of a multi-modal treatment strategy, it can enhance the effectiveness of other therapies. The use of Cytocristin in this context demonstrates its role in improving the overall prognosis for individuals with colorectal cancer.
• Another application of Cytocristin aqueous 1 mg injection is in treating acute leukemia. The injection is effective in targeting the rapidly dividing cancer cells characteristic of this disease. Physicians may use Cytocristin as a key component in a treatment regimen designed to achieve remission. Its role in managing acute leukemia showcases the versatility of this medication in oncology.
Benefits
Cytocristin Aqueous 1 mg Injection is a chemotherapy drug. It is primarily used to treat various types of cancer. It is commonly used to treat acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML), especially when combined with other chemotherapeutic drugs. Its main function is to reduce the presence of leukaemia cells, both in the bone marrow and in the bloodstream. It is also used to treat Hodgkin and non-Hodgkin lymphomas and other lymphoproliferative disorders. It helps to shrink lymphoma tumours. It slows down their growth. It is also used to treat solid cancers such as neuroblastoma, Wilms tumour, rhabdomyosarcoma and Ewing sarcoma. It effectively reduces the size of these tumours. This makes them easier to remove surgically. In children, Cytocristin Aqueous Injection can be used to treat certain brain tumours, including medulloblastoma and ependymoma. It has the potential to help control how the tumour grows and to relieve associated symptoms. In addition, Cytocristin Aqueous 1 mg Injection can be used to treat cancer-related pain. By shrinking tumours that are pressing on nerves or causing discomfort, Cytocristin Aqueous 1 mg Injection can provide pain relief for certain patients. However, it is important to note that while Cytocristin Aqueous 1 mg may offer significant benefits in the treatment of cancer, it may also have potential side effects. For this reason, close monitoring by a team of healthcare professionals is crucial. Common side effects include peripheral neuropathy (tingling or numbness in the extremities), constipation, hair loss and low blood cell count. Patients who are receiving Cytocristin Aqueous 1 mg Injection should be monitored closely for these side effects, and their treatment may be adjusted accordingly to ensure that these problems are managed effectively. It is important to emphasise that Cytocristin Aqueous 1 mg should only be used under the supervision of a qualified oncologist who can assess the risks and benefits specific to each patient.
Side Effects
Like all medicines, this Cytocristin Aqueous 1 mg Injection can cause side effects, although not everybody gets them. Your doctor will discuss these with you and explain the risks and benefits of your treatment.
Most Common Side Effects
• Hair loss
• Headache
• Constipation
• Loss of appetite
• Numbness of feet and arms
• Stomach pain
Common Side Effects
• Severe allergic reaction
• Chest pain
• Breathing problem
• Sepsis
How To Use
Please ensure that Cytocristin Aqueous 1 mg Injection is being administered by a doctor or nurse and do not discontinue use without the advice of your health care professional.
Safety Advice
• Alcohol: It is generally not recommended to drink alcohol while taking Cytocristin Aqueous 1 mg. It may increase the risk of liver damage. it is best to avoid alcohol or limit your alcohol consumption while taking any medication.
• Kidney: Patients with kidney disease should closely monitor kidney function while taking Cytocristin Aqueous 1 mg and report any unusual symptoms or changes in kidney function to their physician. The dose of Cytocristin Aqueous 1 mg should be used with caution in patients with kidney disease. It is important to adjust the dose in patients with kidney disease.
• Breastfeeding: It is not known whether Cytocristin Aqueous 1 mg Injection is excreted in human milk. Because many drugs, including other anthracyclines, are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Cytocristin Aqueous 1 mg Injection, lactating women should be advised not to breastfeed during treatment with Cytocristin Aqueous 1 mg and for at least 7 days after last dose.
• Liver: Cytocristin Aqueous 1 mg Injection should be used with caution in patients with liver disease. It is important that patients with liver disease closely monitor liver function while taking Cytocristin Aqueous 1 mg and report any unusual symptoms or changes in liver function to their doctor. The dose of Cytocristin Aqueous 1 mg may need to be adjusted in patients with liver disease.
• Pregnancy: Use of Cytocristin Aqueous 1 mg Injection may be unsafe during pregnancy as animal studies indicate that it may harm the developing foetus. However, if you are pregnant or planning to become pregnant, it is important to talk to your doctor about the potential risks and benefits of taking Cytocristin Aqueous 1 mg during pregnancy. Your doctor will be able to help you make the best decision for you and your baby's health.
• Driving: Cytocristin Aqueous 1 mg Injection may cause dizziness, fatigue, and difficulty concentrating and coordinating, which may affect your ability to drive a vehicle safely. It is important to follow your doctor's instructions and take necessary precautions such as avoiding driving a vehicle or operating heavy machinery if you suffer from the side effects of this Cytocristin Aqueous 1 mg.